{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:15:23Z","timestamp":1768461323575,"version":"3.49.0"},"reference-count":30,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1667,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,7]]},"DOI":"10.1111\/j.1365-2516.2010.02464.x","type":"journal-article","created":{"date-parts":[[2011,2,8]],"date-time":"2011-02-08T03:29:43Z","timestamp":1297135783000},"page":"625-629","source":"Crossref","is-referenced-by-count":25,"title":["Recombinant factor concentrates may increase inhibitor development: a single centre cohort study"],"prefix":"10.1111","volume":"17","author":[{"given":"T.","family":"STRAUSS","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"LUBETSKY","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"RAVID","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"BASHARI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"LUBOSHITZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"LALEZARI","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"MISGAV","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"U.","family":"MARTINOWITZ","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"KENET","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,2,7]]},"reference":[{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1046\/j.1365-2516.2001.00545.x","article-title":"Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy","volume":"7","author":"Fischer","year":"2001","journal-title":"Haemophilia"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1365-2796.1992.tb00546.x","article-title":"Twenty-five years\u2019 experience of prophylactic treatment in severe hemophilia A and B","volume":"232","author":"Nilsson","year":"1992","journal-title":"J Intern Med"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/j.1538-7836.2008.02852.x","article-title":"Inhibitor incidence with recombinant vs. Plasma-derived FVIII in previously untreated patients with severe hemophilia A: homogenous results from for published observational studies","volume":"6","author":"Calvez","year":"2008","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1365-2516.2006.01418.x","article-title":"Early factor VIII exposure and subsequent inhibitor development in children with severe haemophilia A","volume":"13","author":"Chalmers","year":"2007","journal-title":"Haemophilia"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1055\/s-0037-1614251","article-title":"Comparison of high responder inhibitor frequency in recent studies of previously untreated patients with hemophilia A","volume":"79","author":"Ehrlich","year":"1998","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB6|cit6","first-page":"19","volume-title":"Factor VIII inhibitors","author":"Gill","year":"1984"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/blood-2006-11-056317","article-title":"Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study","volume":"109","author":"Gouw","year":"2007","journal-title":"Blood"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/j.1538-7836.2007.02595.x","article-title":"Treatment characteristics and the risk of inhibitor development: a multicenter cohort study among previously untreated patients with severe hemophilia A","volume":"5","author":"Gouw","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1365-2516.2005.00921.x","article-title":"Prophylactic treatment effects on inhibitor risk: experience in one centre","volume":"11","author":"Morado","year":"2005","journal-title":"Haemophilia"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1055\/s-0038-1649954","article-title":"Haemophilia A: mutation type determines risk of inhibitor formation","volume":"74","author":"Schwaab","year":"1995","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1046\/j.1538-7836.2003.00230.x","article-title":"Intensive exposure to factor VIII is a risk factor for inhibitor development in mild hemophilia A","volume":"1","author":"Sharathkumar","year":"2003","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1046\/j.1365-2516.2003.00780.x","article-title":"The epidemiology of inhibitors in haemophilia A: a systematic review","volume":"9","author":"Wight","year":"2003","journal-title":"Haemophilia"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/0140-6736(93)91593-B","article-title":"Frequency of inhibitor development in haemophiliacs treated with low-purity factor VIII","volume":"342","author":"Addiego","year":"1993","journal-title":"Lancet"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB14|cit14","first-page":"1620","article-title":"High titer inhibitors in severe haemophilia A. A meta-analysis based on eight long-term follow-up studies concerning inhibitors associated with crude or intermediate purity factor VIII products","volume":"72","author":"Briet","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S0037-1963(01)90109-X","article-title":"Clinical evaluation of B-Domain deleted recombinant factor VIII in previously untreated patients","volume":"38","author":"Courter","year":"2001","journal-title":"Sem Hematol"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1055\/s-0038-1642479","article-title":"Incidence of factor VIII inhibitor development in hemophilia A patients treated with less pure plasma derived concentrates","volume":"71","author":"De Biasi","year":"1994","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1365-2516.2006.01201.x","article-title":"Occurrence of inhibitors in previously untreated or minimally treated patients with haemophilia A after exposure to a plasma-derived solvent-detergent factor VIII concentrate","volume":"12","author":"Gringeri","year":"2006","journal-title":"Haemophilia"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1056\/NEJM199302183280701","article-title":"Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A","volume":"328","author":"Lusher","year":"1993","journal-title":"New Engl J Med"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1182\/blood.V81.12.3332.3332","article-title":"Incidence of inhibitor development in a group of young hemophilia patients treated exclusively with lyophilized cryoprecipitate","volume":"81","author":"Peerlinck","year":"1993","journal-title":"Blood"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1111\/j.1538-7836.2010.03823.x","article-title":"Rate of inhibitor development in previously-untreated hemophilia a patients treated with plasma-derived or recombinant factor VIII concentrates. A systematic review","volume":"8","author":"Iorio","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1111\/j.1365-2516.2006.01373.x","article-title":"Recombinant vs. plasma-derived products, especially those with intact VWF, regarding inhibitor development","volume":"12","author":"Escuriola Ettingshausen","year":"2006","journal-title":"Haemophilia"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2005-04-1371","article-title":"Influence of the type of factor VIII concentrate on the incidence of factor VIII inhibitors in previously untreated patients with severe hemophilia A","volume":"107","author":"Goudemand","year":"2006","journal-title":"Blood"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1055\/s-2002-32664","article-title":"Inhibitor development in previously untreated patients with hemophilia A: a prospective long-term follow-up comparing plasma-derived and recombinant products","volume":"28","author":"Kreuz","year":"2002","journal-title":"Sem Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1055\/s-0037-1615358","article-title":"French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII: Incidence of inhibitor and evaluation of immune tolerance","volume":"80","author":"Rothschild","year":"1998","journal-title":"Thromb Haemost"},{"issue":"Suppl. 2","key":"10.1111\/j.1365-2516.2010.02464.x-BIB25|cit25","article-title":"Early exposure to recombinant factor concentrates may increase inhibitor development: a single center cohort study","volume":"14","author":"Strauss","year":"2008","journal-title":"Haemophilia"},{"issue":"Suppl 5","key":"10.1111\/j.1365-2516.2010.02464.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2516.2010.02318.x","article-title":"Prophylaxis in the haemophilia population","volume":"16","author":"Blanchette","year":"2010","journal-title":"Haemophilia"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1046\/j.1365-2796.2000.00633.x","article-title":"Primary prophylaxis for individuals with severe haemophilia: how many hospital visits could treatment prevent?","volume":"247","author":"Miners","year":"2000","journal-title":"J Int Med"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1046\/j.1365-2141.2001.02828.x","article-title":"Incidence of factor VIII inhibitors in severe haemophilia: the importance of patient age","volume":"113","author":"Lorenzo","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1055\/s-0038-1657681","article-title":"Absence of inhibitors in previously untreated patients with severe haemophilia A after exposure to a singe intermediate purity factor VIII product","volume":"78","author":"Yee","year":"1997","journal-title":"Thromb Haemost"},{"key":"10.1111\/j.1365-2516.2010.02464.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1365-2516.2009.02122.x","article-title":"New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development","volume":"16","author":"Kurnik","year":"2010","journal-title":"Haemophilia"}],"container-title":["Haemophilia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2516.2010.02464.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1365-2516.2010.02464.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,4]],"date-time":"2021-07-04T10:10:59Z","timestamp":1625393459000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2516.2010.02464.x"}},"subtitle":["EARLY EXPOSURE TO RECOMBINANT FACTOR INCREASE INHIBITOR DEVELOPMENT"],"short-title":[],"issued":{"date-parts":[[2011,2,7]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,7]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1365-2516.2010.02464.x","relation":{},"ISSN":["1351-8216"],"issn-type":[{"value":"1351-8216","type":"print"}],"subject":[],"published":{"date-parts":[[2011,2,7]]}}}